Hengrui Pharma(SH:600276) Zhi Tong Cai Jing·2025-09-23 10:11Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-3095 tablets, aimed at treating chronic spontaneous urticaria (CSU) patients [1] Group 1: Product Development - HRS-3095 tablets are a small molecule compound targeting immune cells, developed independently by the company, showing promising therapeutic effects for allergic diseases [1] - Preclinical data indicates that HRS-3095 can effectively improve skin allergy symptoms in mice [1] - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1] Group 2: Market Context - Currently, there are no approved drugs targeting the same mechanism for CSU in both domestic and international markets [1]